Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Losartan Potassium NDC 68788-4007 by Preferred Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Losartan Potassium Tab USP 25mg - 8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
This text provides information on a clinical study involving Atenolol and Losartan Potassium. It mentions the percentage of patients reaching the primary endpoint, an adjusted risk reduction of 13% with a p-value of 0.021. The timeline of the study is also indicated, with the months labeled from 0 to 66.*
Figure 2 - spl image3 figure2
This text provides information comparing the risk reduction of Atenolol and Losartan Potassium, with an adjusted risk reduction of 25% and a p-value of 0.001. It also shows the percentage of patients with fatal/non-fatal stroke across different study months from 6 to 66.*
Figure 3 - spl image4 figure3
This text provides data on primary endpoint events within demographic subgroups from a study comparing the efficacy of Losartan Potassium and Atenolol in preventing stroke (fatal/non-fatal). The demographic subgroups analyzed include age, gender, race, presence of isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). The results are presented in terms of event rates, hazard ratios, and confidence intervals. The study adjusted for baseline Framingham risk score and left ventricular hypertrophy levels. The sample sizes for each subgroup are represented proportionally by symbols.*
Figure 4 - spl image5 figure4
This is a graph showing the percentage of patients with an event over a period of 48 months for Losartan Potassium compared to a Placebo. The risk reduction is calculated to be 16.1% with a statistically significant p-value of 0.022.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
